gc101 til
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 8, 2023 (NCT06120712)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07294872 | Phase 1 | Dec 8, 2025 | Government of China, University of Electronic Science and Technology of China |
| NCT06703398 | Phase 2 | Dec 20, 2024 | Government of China |
| NCT06120712 | Phase 1/Phase 2 (Phase 2) | Nov 8, 2023 | Government of China, Peking University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 2 | 2023 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Electronic Science and Technology of China | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1